| In a previous study, the ethanolic extract of andaliman fruit (Zanthoxylum acanthopodium) has been reported to exert potential anti-inflammatory and anti-diabetes activities by ameliorating gene markers related to inflammation and diabetes in vitro. Here, andaliman ethanolic extract was formulated into a lozenge tablet and further tested for its functional efficacy to prevent metabolic syndrome through antioxidant and inhibitory enzyme activity against alpha-glucosidase and lipase in vitro. The lozenge was made from andaliman ethanolic extract and formulated in 3 variants, i.e. original andaliman lozenge, andaliman lozenge with honey additive, and andaliman lozenge with sorbitol additive. Gas chromatography-mass spectrometry (GC/MS) profiling showed that all andaliman lozenges contained limonene as a major essential compound found in andaliman extract. All lozenges were able to scavenge >50% of free radicals, indicating their antioxidant potency. This is also linear with their total phenolic contents (~160 GAE/mL). Andaliman lozenges also blocked alpha-glucosidase (50-70%) and lipase activities (~50%). Organoleptic results showed that among all, most panellists prefer andaliman lozenge with sorbitol additive over others. In conclusion, andaliman lozenges may offer an alternative functional supplement for the prevention of metabolic syndrome. |